Posts

AZ stays on track for $80B revenue goal as cancer meds, rare disease sales help offset Ultomiris miss

on

Enhertu Approved in the EU as First Tumor Agnostic HER2-Directed Therapy for Previously Treated HER2-Positive Metastatic Solid Tumors

on

Daiichi Sankyo Targets Nearly $15B in Oncology Sales by 2030 via ADC Franchise Expansion

on

Daiichi Sankyo's ADC Manufacturing Investments and Market Position

on

FDA Action Alert: Upcoming Decisions on Argenx, AstraZeneca/Daiichi Sankyo, Biogen/Eisai, and Cingulate

on

FDA Approves Enhertu-Perjeta Combo for First-Line Treatment of HER2+ Metastatic Breast Cancer

on

Pfizer's Tukysa Shows Strong PFS Benefit in First-Line HER2+ Breast Cancer Maintenance at SABCS 2025, Sparking Debate with Enhertu

on

ESMO Spotlight: Flagship ADCs move into early-stage cancer to validate chemo-displacement ambitions

on

AstraZeneca Furthers Ambition to Redefine Cancer Care with First Data from Four Major Pivotal Trials at ESMO 2025

on

AstraZeneca Beats Q2 Estimates on Strong Cancer Drug Sales

on

AstraZeneca, Daiichi say Enhertu delivers 'highly statistically significant' efficacy in first-line breast cancer

on

FDA Approves Roche's PATHWAY HER2 Test for HER2-Ultralow Metastatic Breast Cancer

on

Enhertu Secures 7th FDA Approval for Expanded Use in HER2-Low and HER2-Ultralow Breast Cancer

on